Search Results
Your search for ,UsE matches 11239 pages
Showing 51 - 100Induction Nivolumab Before CRT in High-Risk HPV-Driven Oropharyngeal Cancer
In a French phase II trial (IMMUNEBOOST-HPV) reported in the Journal of Clinical Oncology, Mirghani et al found that use of induction nivolumab prior to chemoradiation (CRT) did not meet the endpoint of ‘receipt of full treatment in due time’ (FTDT) in patients with high-risk human papillomavirus...
ASH Publishes Clinical Guidelines on AL Amyloidosis Diagnosis
The American Society of Hematology (ASH) has released clinical practice guidelines on the diagnosis of light chain (AL) amyloidosis, which were published in Blood Advances. Additionally, the expert panel behind the guidelines also published a scoping review about the clinical features of systemic...
FDA Approves TTFields Device for Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a portable, noninvasive device that delivers alternating electrical fields, known as tumor treating...
ASH 2025: Myelofibrosis Roundup
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
Epcoritamab Plus R2 in Follicular Lymphoma: A Potential New Treatment Standard
In patients with follicular lymphoma who received at least one prior line of therapy, the combination of the bispecific antibody epcoritamab-bysp and rituximab–lenalidomide (R2) reduced the risk of disease progression or death by almost 80% over R2 alone, based on the primary analysis of the phase...
GIMEMA ALL2820: Chemotherapy-Free Regimen Studied in Front-Line Setting
As front-line therapy, a chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed standard treatment with imatinib plus chemotherapy in adults with newly diagnosed Philadelphia chromosome–positive...
ASCO and Conexiant Launch ASCO AI in Oncology
The American Society of Clinical Oncology (ASCO®) and Conexiant today announced the launch of ASCO AI in Oncology, a premier digital destination designed to help oncology professionals navigate the transformative role of artificial intelligence (AI) in cancer care. Launching this initiative marks...
MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma
For patients with previously treated multiple myeloma, the greatest risk reduction yet achieved in a phase III clinical trial was reported with the BCMA-directed CD3 T-cell engager teclistamab-cqyv plus daratumumab and hyaluronidase-fihj. Treatment with this combination resulted in an 83% reduction ...
Guidelines Harmonize Pan-Tumor Pathologic Response to Neoadjuvant Therapy
The first unified, pan-tumor guideline framework has been released for how pathologists should evaluate and score response in the neoadjuvant setting. These consensus guidelines, which were a joint effort by the Society for Immunotherapy of Cancer's (SITC) Pan-tumor Harmonization of Pathologic...
A Paradigm Shift in Treating Adult AML?
The scientific revolution in determining the genetic basis of cancer is finally bearing fruit in hematologic neoplasms such as acute myeloid leukemia (AML), where over the past decade a number of effective new drugs have expanded our armamentarium and provided effective—and in some cases...
FDA Provides Safety Labeling Update for Capecitabine and Fluorouracil on Risks Associated With DPD Deficiency
The U.S. Food and Drug Administration (FDA) has provided communication to increase awareness of recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil—indicated for colorectal, breast, gastric/esophageal/gastroesophageal, and pancreatic cancers—related to risks associated...
Colorectal Cancer Liver Metastases: Transplant or Resect?
Colorectal metastases isolated to the liver no longer portend a universally fatal outcome. In 2024, the TransMet study1demonstrated that liver transplantation in select patients could be life-saving—thus changing the treatment paradigm—but so can surgical resection when appropriately applied....
WHO Analysis Finds Nearly 40% of Global Cancer Cases Attributable to Modifiable Risk Factors
Almost 40% of all new cancer cases could be attributed to at least one of 30 modifiable risk factors, according to a new global analysis from the World Health Organization (WHO) and its International Agency for Research on Cancer (IARC). The analysis of preventable cancers was published in Nature...
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
“Dripping water hollows out stone, not through force but through persistence.” – Ovid The 2025 American Society of Hematology (ASH) Annual Meeting & Exposition delivered multiple practice-changing data sets surrounding T-cell–redirecting therapies in relapsed or refractory multiple myeloma....
World Cancer Day 2026: UICC’s Campaign ‘United by Unique’
As the organizer of World Cancer Day on February 4, the Union for International Cancer Control (UICC) is mobilizing organizations and individuals worldwide to ensure that the voices of people affected by cancer are heard and drive a new vision of cancer care. Now in its second year, the World...
Oxybutynin May Improve ADT-Induced Hot Flashes in Patients With Prostate Cancer
The use of oxybutynin led to statistically significant reductions in the number of hot flashes per day compared with placebo for men with prostate cancer receiving androgen-deprivation therapy (ADT), according to findings from the Alliance A222001 trial published in the Journal of Clinical...
Case 1: Management of Early Relapsed DLBCL
This is Part 1 of Personalizing Treatment Pathways in Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Jeremy Abramson, J. Erika Haydu, and Jacob Soumerai discuss the treatment of early relapsed...
Studies Move Away From Whole-Brain Radiotherapy Standard of Care for SCLC
When patients with small cell lung cancer (SCLC) progress, as is common with such an aggressive malignancy, brain metastasis is a known possibility. As such, guidelines have recommended prophylactic cranial irradiation for patients with SCLC who respond well to first-line therapy to decrease the...
Pirtobrutinib Improves Progression-Free Survival vs Bendamustine/Rituximab in Front-Line CLL/SLL
The first prospective, randomized phase III trial of a noncovalent Bruton’s tyrosine kinase (BTK) inhibitor exclusively in treatment-naive patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)—BRUIN CLL-313—demonstrated a statistically significant and clinically...
Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma
A response-adapted approach to treatment decision-making for patients with resectable cutaneous squamous cell carcinoma demonstrated that with the use of neoadjuvant pembrolizumab, many patients could avoid surgery and/or radiotherapy. Findings from the De-Squamate study were published in the...
Head and Neck Cancer: How Does Genetic Ancestry Impact Tumor Genomics?
Genetic ancestry plays a key role in determining the behavior of head and neck tumors and may help explain why African American patients survive for half as long as their counterparts of European ancestry, according to a new review study published by Ndahayo et al in Cancer and Metastasis Reviews....
Randomized Trial Shows AI-Supported Mammography Improves Sensitivity and Lowers Interval Cancer Rate
A randomized, controlled clinical trial for artificial intelligence (AI)–supported mammography readings, called the MASAI trial, demonstrated that AI reads of mammogram scans led to fewer interval breast cancer diagnoses than with standard double reads by radiologists, according to findings...
AACR Announces Fellows of the AACR Academy Class of 2026
The American Association for Cancer Research (AACR) has announced its newly elected 2026 class of Fellows of the AACR Academy. The Fellows of the AACR Academy was established to honor scientists, clinicians, and physician-scientists whose visionary work has reshaped the landscape of cancer...
Consensus Recommendations Developed for Use of Liquid Nitrogen Spray Cryotherapy in Barrett's Esophagus, Esophageal Cancer
The Spray Cryotherapy Esophageal Consortium has developed a set of expert and evidence-based consensus recommendations guiding the use of liquid nitrogen spray cryotherapy in Barrett's esophagus and esophageal cancer. The recommendations, decided upon through a modified Delphi process, were...
Machine Learning–Enhanced Prognostic Scoring Predicts Survival and Classifies Risk From Spinal Metastases
A prognostic scoring system for predicting 1-year survival in patients with advanced cancer and spinal metastases was enhanced with machine learning for greater accuracy, according to the results of a Japanese multicenter study published in Spine. "This model provides a practical risk assessment...
American College of Surgeons Publishes Annual NCDB Report
The second annual report from the National Cancer Database (NCDB) of the American College of Surgeons (ACS) documents a substantial rise in neoadjuvant treatments, such as chemotherapy, immunotherapy, and hormone therapy, often allowing for less invasive surgery and helping clinicians assess how a...
Updated Analysis of CARTITUDE-4: Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple Myeloma
As reported in The Lancet Oncology by Einsele et al, an updated analysis of the phase III CARTITUDE-4 trial has shown that a single infusion of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, prolonged overall survival vs...
Is Long-Term PPI Use Associated With Increased Gastric Cancer Risk?
Long-term proton pump inhibitor (PPI) use may not be associated with an increased risk of gastric adenocarcinoma, according to findings from a Nordic health study published by Duru et al The BMJ. According to the report's authors, “This finding should offer relief for patients needing long-term...
Associations Found Between Air Pollutants and Lung Cancer Subtypes
Both particulate and gaseous air pollutants were linked with subtypes of lung cancer, according to a study published by Diver et al in Environmental Pollution. The analysis, led by investigators from the Barcelona Institute for Global Health (ISGlobal) and the American Cancer Society, showed that...
CRI Launches Open Database for Immunotherapy Cancer Research
The Cancer Research Institute (CRI) in collaboration with 10x Genomics, Stanford University School of Medicine, the University of Pennsylvania Perelman School of Medicine, and Memorial Sloan Kettering Cancer Center, has launched an open foundational database for cancer immunotherapy research. The...
Evolving Treatment Landscape Spurs Living Guideline Update on Multiple Myeloma
ASCO, in collaboration with Ontario Health (Cancer Care Ontario), has published an update to their previous guideline on the treatment of multiple myeloma.1 This new guideline—which has been selected as an ASCO Living Guideline—reflects dramatic changes that have helped improve the management of...
Case 2: De Novo Metastatic PIK3CA-Altered HR-Positive/HER2-Negative Breast Cancer and Non–Insulin-Dependent Diabetes
This is Part 2 of Balancing Benefit and Burden: Managing Toxicities in HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Neil Iyengar, Sara Tolaney, and William Gradishar...
Most Patients Support Use of AI in Mammogram Readings, Survey Reveals
The results of a recent survey showed that patients largely support the use of artificial intelligence (AI) to aid radiologists in reading mammograms. The findings, which were published in Breast Cancer Research and Treatment, also indicated acceptance varied in association with factors such as...
FDA Releases Draft Guidance for Use of MRD and CR as Primary Endpoints in Multiple Myeloma Trials
On January 20, 2026, the U.S. Food and Drug Administration (FDA) released a draft guidance for industry regarding the use of minimal residual disease and complete response as primary endpoints in clinical trials evaluating drugs and biologics for the treatment of patients with multiple myeloma that ...
Investigational Vaccine Could Prevent Cancer Development in Lynch Syndrome Carriers
An investigational cancer vaccine, NOUS-209, has shown potential for intercepting precancerous and cancerous cells before the disease can develop in individuals with Lynch syndrome, thereby showing the potential to prevent cancer from developing in these high-risk individuals, according to findings ...
Regulatory Agencies Establish Principles of Good AI Use in Drug Development
The U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have collaborated with the European Medicines Agency (EMA) to develop a set of 10 guiding principles for good uses of artificial intelligence (AI) in...
What Is Causing a Rise in Early-Onset Gastrointestinal Cancers, Including Pancreatic Cancer?
Although it’s been widely reported for years that colorectal cancer incidence has been increasing among younger adults under age 50 by between 1% and 2% annually since the mid-1990s,1 two new studies by Kimmie Ng, MD, MPH, Associate Chief of the Division of Gastrointestinal Oncology and Founding...
Global Cancer Survival Gaps Assessed Using a Country-Level Machine-Learning Framework
A machine-learning model has calculated country-specific cancer mortality-to-incidence ratios and evaluated the factors that contribute the most to each country's survival gaps. Additionally, the artificial intelligence (AI) tool mapped out actions each country could take to improve cancer...
Improved Contralateral Breast Cancer Risk Knowledge With Personalized Counseling Tool
Patients with unilateral breast cancer who underwent quantitative counseling with a personalized tool incorporating genetic testing results were better informed of their contralateral breast cancer risk compared with those who received standard counseling, according to results from the GET FACTS...
Machine Learning Approach Accelerates Discovery of Novel CDK9 Inhibitors
A virtual screening campaign using machine learning identified molecules with potential for development as novel CDK9 inhibitors for the treatment of cancer, according to early research findings published in Biomolecules. Integration of artificial intelligence (AI) into the drug discovery phase...
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
A deep learning model demonstrated the ability to predict breast cancer recurrence risk and possible benefit from the addition of chemotherapy based on histopathologic images rather than genomic testing in patients with hormone receptor–positive, HER2-negative breast cancer, according to findings...
Novel Endocrine Therapy, Giredestrant, Improves Invasive Disease–Free Survival in Estrogen Receptor–Positive, HER2-Negative Early Breast Cancer
Giredestrant, a next-generation oral selective estrogen receptor degrader (SERD) and full antagonist, significantly improved invasive disease–free survival as adjuvant treatment for patients with estrogen receptor–positive, HER2-negative early breast cancer compared with standard-of-care endocrine...
Nivolumab Plus AVD Reduces Disease Progression Risk in Adolescents With Advanced Classical Hodgkin Lymphoma
A combination of nivolumab with AVD chemotherapy (doxorubicin, vinblastine, and dacarbazine) demonstrated a significant reduction in the risk of disease progression or death compared with brentuximab vedotin plus AVD in adolescent patients with newly diagnosed advanced classical Hodgkin lymphoma,...
Whole-Genome Sequencing–Based Classifier Better Predicts Homologous Recombination Deficiency Across Cancer Types
A whole-genome sequencing–based classifier demonstrated greater performance for predicting homologous recombination deficiency (HRD) across cancer types than standard assays, which in turn determined which patients with cancer would benefit from treatment with PARP inhibitors, according to findings ...
Multiple Myeloma: Sex Differences in Etiology and Clinical Presentation
Rates of multiple myeloma, the second most common blood cancer in the United States, are increasing and are twice as high in men than in women. A new study published by Ong et al in the journal Cancer provides insights that may help to explain this disparity. To investigate the sex difference in...
Addition of Nivolumab to Docetaxel in ARPI-Pretreated, Chemotherapy-Naive Advanced Prostate Cancer
As reported in The Lancet Oncology by Fizazi et al, the phase III CheckMate 7DX trial showed no progression-free or overall survival benefit with the addition of nivolumab to docetaxel in patients with androgen receptor pathway inhibitor (ARPI)–pretreated and chemotherapy-naive metastatic...
MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma
For patients with previously treated multiple myeloma, the greatest risk reduction yet achieved in a phase III clinical trial was reported with the BCMA-directed CD3 T-cell engager teclistamab-cqyv plus daratumumab and hyaluronidase-fihj. Treatment with this combination resulted in an 83% reduction ...
Can KDM6A Mutations Help Guide Treatment Selection in Bladder Cancer?
Mutations in KDM6A have been identified as a regulator of therapeutic responses in advanced bladder cancer, sensitizing tumors to anti–PD-1 immune checkpoint inhibition but resisting cisplatin chemotherapy, according to early research published in Nature Communications. Based on this and further...
Small Study Examines Potential of Artificial Saliva in Patients With Head and Neck Cancer
An artificial saliva in the form of a mouthwash, produced with a protein extracted from sugarcane and modified in a laboratory, may aid in treating hyposalivation among patients with head and neck cancer, a new study has found. Radiotherapy delivered very close to the mouth can destroy salivary...
Are Food Preservatives Linked to Increased Cancer Risk?
Higher intake of food preservatives, widely used in industrially processed foods and beverages to extend shelf life, is associated with a modestly increased risk of cancer, according to the results of a French study published by Hasenböhler et al in The BMJ. While further research is needed to...
